PEG Stock Overview
Through its subsidiary, Reponex Pharmaceuticals A/S, a clinical-stage biopharmaceutical company, develops treatments for diseases that have patient and social impact for which current therapy is lacking or in need of improvement. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Pharma Equity Group A/S Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | DKK 0.18 |
| 52 Week High | DKK 0.45 |
| 52 Week Low | DKK 0.14 |
| Beta | 0 |
| 1 Month Change | 13.69% |
| 3 Month Change | -24.68% |
| 1 Year Change | -57.70% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -76.20% |
Recent News & Updates
Is Pharma Equity Group (CPH:PEG) A Risky Investment?
Dec 11
Would Pharma Equity Group (CPH:PEG) Be Better Off With Less Debt?
Aug 28Shareholder Returns
| PEG | DK Real Estate | DK Market | |
|---|---|---|---|
| 7D | 0.3% | -1.0% | -12.2% |
| 1Y | -57.7% | -6.7% | -4.9% |
Return vs Industry: PEG underperformed the Danish Real Estate industry which returned -8% over the past year.
Return vs Market: PEG underperformed the Danish Market which returned -8% over the past year.
Price Volatility
| PEG volatility | |
|---|---|
| PEG Average Weekly Movement | 9.5% |
| Real Estate Industry Average Movement | 4.0% |
| Market Average Movement | 4.3% |
| 10% most volatile stocks in DK Market | 10.5% |
| 10% least volatile stocks in DK Market | 2.8% |
Stable Share Price: PEG's share price has been volatile over the past 3 months compared to the Danish market.
Volatility Over Time: PEG's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of Danish stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2002 | n/a | Thomas Selsø | www.pharmaequitygroup.com |
Pharma Equity Group A/S, through its subsidiary, Reponex Pharmaceuticals A/S, a clinical-stage biopharmaceutical company, develops treatments for diseases that have patient and social impact for which current therapy is lacking or in need of improvement. Its products under development that are in Phase II clinical trials include RNX-011 for the treatment of bacterial peritonitis; RNX-021, RNX-022, and RNX-023 for the treatment of chronic skin ulcers; RNX-041 for the treatment of inflammatory bowel diseases, such as chrons and pouchitis; and RNX-051 for the treatment of colorectal cancer and colon adenoma. The company was incorporated in 2002 and is based in Hørsholm, Denmark.
Pharma Equity Group A/S Fundamentals Summary
| PEG fundamental statistics | |
|---|---|
| Market cap | DKK 219.12m |
| Earnings (TTM) | -DKK 30.81m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-7.1x
P/E RatioIs PEG overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PEG income statement (TTM) | |
|---|---|
| Revenue | DKK 0 |
| Cost of Revenue | DKK 0 |
| Gross Profit | DKK 0 |
| Other Expenses | DKK 30.81m |
| Earnings | -DKK 30.81m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.025 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 168.1% |
How did PEG perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/23 05:37 |
| End of Day Share Price | 2024/12/23 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Pharma Equity Group A/S is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|